Recent AUTL News
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:35:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:46 PM
- Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO • GlobeNewswire Inc. • 05/31/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/17/2024 08:39:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 12:27:03 PM
- Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 05/17/2024 11:00:00 AM
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress • GlobeNewswire Inc. • 05/14/2024 02:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/13/2024 01:33:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:23:04 AM
- Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO • GlobeNewswire Inc. • 04/24/2024 02:00:00 PM
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/23/2024 11:00:00 AM
- Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Autolus Therapeutics Announces Changes to its Board of Directors • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates • GlobeNewswire Inc. • 03/14/2024 11:00:00 AM
- Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site • GlobeNewswire Inc. • 03/12/2024 11:00:00 AM
- Autolus Therapeutics announces publication in Blood Cancer Journal • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/23/2024 10:28:32 PM
- Autolus Therapeutics announces publication in Nature Communications • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/21/2024 10:01:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:37:20 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/09/2024 10:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:17:55 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM